FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML
- 20 November 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 146 (21) , 2608-2611
Abstract
FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin) with venetoclax shows promise as frontline pediatric acute myeloid leukemia therapy. In 12 patients treated at MD Anderson, most achieved remission with good early survival outcomes, and many proceeded to transplant. Common toxicities included cytopenias, comparable to previous regimens.Keywords
This publication has 25 references indexed in Scilit:
- Dosing of Venetoclax in Pediatric Patients with Relapsed Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response RelationshipsClinical Therapeutics, 2024
- Investigation of infections status in pediatric patients with acute myeloid leukemia during the induction period–a retrospective study in two medical centersAnnals of Hematology, 2024
- Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemiaPediatric Blood & Cancer, 2024
- Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasmsPediatric Blood & Cancer, 2023
- Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic SyndromeClinical Hematology International, 2023
- Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemiaAmerican Journal of Hematology, 2022
- Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation studyThe Lancet Oncology, 2020
- Acute myeloid leukemia drug development in the post‐venetoclax eraAmerican Journal of Hematology, 2019
- Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012Leukemia, 2018